Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ · Healthcare
Monte Rosa Therapeutics, Inc. Shareholder Equity 2023–2025
Monte Rosa Therapeutics, Inc. annual/quarterly shareholder equity history from 2023 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Monte Rosa Therapeutics, Inc. shareholder equity for the quarter ending December 31, 2025 were 233.1M, a 4.54% increase year-over-year.
- Monte Rosa Therapeutics, Inc. shareholder equity for 2025 were 233.1M, a 4.54% increase from 2024.
- Monte Rosa Therapeutics, Inc. shareholder equity for 2024 were 222.9M, a 24.37% increase from 2023.
- Monte Rosa Therapeutics, Inc. shareholder equity for 2023 were 179.3M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Monte Rosa Therapeutics, Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $233 |
| 2024 | $223 |
| 2023 | $179 |
| Monte Rosa Therapeutics, Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $233 |
| 2024-12-31 | $223 |
| 2023-12-31 | $179 |
Monte Rosa Therapeutics, Inc. Shareholder Equity — FAQ
Monte Rosa Therapeutics, Inc. (GLUE) shareholder equity over the last 3 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see GLUE's shareholder equity history?
The chart and table above show Monte Rosa Therapeutics, Inc.'s shareholder equity by year and by quarter, including the growth rate.